Comparative Effectiveness of Carbazochrome Sulphonate (AC-17) Combined with Vitamin C and Vitamin K Versus Vitamin C and Vitamin K in Managing Hemoptysis in Pulmonary Tuberculosis Patients

Abstract

Background and Objectives. Hemoptysis is a common and severe complication of pulmonary tuberculosis (TB), often requiring prompt intervention. While conventional therapies with vitamin K and C are used, their effectiveness may be limited in cases of significant vascular damage. Carbazochrome Sulfonate (AC-17) has been suggested as a potential adjunctive treatment to enhance hemostasis. This study aimed to evaluate the efficacy of Carbazochrome Sulfonate (AC-17) in combination with vitamin K and vitamin C, compared to vitamin K and C alone, in reducing the duration of hemoptysis in patients with pulmonary TB.

Materials and Methods. A comparative observational study was conducted at Wahidin Sudirohusodo Hospital and Labuang Baji Hospital, involving 60 pulmonary TB patients with hemoptysis. The treatment group received AC-17 (50 mg IV) along with vitamin K and C, while the control group received only vitamins K and C. The primary outcome was the duration of hemoptysis, and statistical analysis was performed using Chi-square and t-tests.

Results. The treatment group had a significantly shorter mean duration of hemoptysis (4.03 days) compared to the control group (6.56 days; p = 0.002). Ninety-three percent of the treatment group stopped bleeding within 7 days, compared to 50% in the control group.

Conclusions. AC-17, when combined with vitamin K and C, significantly reduced the duration of hemoptysis in pulmonary TB patients. These findings suggest AC-17 as an effective adjunct in hemostatic therapy for TB-related hemoptysis.